Sonoma Pharmaceuticals Inc (SNOA) - Net Assets
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) has net assets worth $3.43 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.62 Million) and total liabilities ($10.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Sonoma Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.43 Million |
| % of Total Assets | 25.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | -17.75% |
| 10-Year Change | -56.5% |
| Growth Volatility | 101.57 |
Sonoma Pharmaceuticals Inc - Net Assets Trend (2003–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Sonoma Pharmaceuticals Inc (SNOA) total assets for the complete picture of this company's asset base.
Annual Net Assets for Sonoma Pharmaceuticals Inc (2003–2025)
The table below shows the annual net assets of Sonoma Pharmaceuticals Inc from 2003 to 2025. For live valuation and market cap data, see Sonoma Pharmaceuticals Inc (SNOA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $4.41 Million | -28.12% |
| 2024-03-31 | $6.14 Million | -23.07% |
| 2023-03-31 | $7.98 Million | -8.28% |
| 2022-03-31 | $8.70 Million | +62.17% |
| 2021-03-31 | $5.36 Million | -4.64% |
| 2020-03-31 | $5.62 Million | -46.38% |
| 2019-03-31 | $10.49 Million | -31.56% |
| 2018-03-31 | $15.33 Million | -28.49% |
| 2017-03-31 | $21.43 Million | +111.35% |
| 2016-03-31 | $10.14 Million | -15.88% |
| 2015-03-31 | $12.05 Million | -0.07% |
| 2014-03-31 | $12.06 Million | +195.59% |
| 2013-03-31 | $4.08 Million | +570.16% |
| 2012-03-31 | $-868.00K | -151.03% |
| 2011-03-31 | $1.70 Million | -75.86% |
| 2010-03-31 | $7.04 Million | +210.49% |
| 2009-03-31 | $2.27 Million | -85.29% |
| 2008-03-31 | $15.43 Million | +3.54% |
| 2007-03-31 | $14.90 Million | +103.07% |
| 2006-03-31 | $7.34 Million | +233.24% |
| 2005-03-31 | $2.20 Million | +2887.34% |
| 2003-03-31 | $-79.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sonoma Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19780600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-4.38 Million | -99.21% |
| Other Components | $206.59 Million | 4683.59% |
| Total Equity | $4.41 Million | 100.00% |
Sonoma Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Sonoma Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Korab Resources Ltd
AU:KOR
|
$2.08 Million |
|
Signing Day Sports, Inc.
NYSE MKT:SGN
|
$2.08 Million |
|
Constellation Technologies Ltd
AU:CT1
|
$2.09 Million |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
$2.09 Million |
|
Keystone Law Group PLC
LSE:KEYS
|
$2.08 Million |
|
Greenwave Technology Solutions Inc. Common Stock
NASDAQ:GWAV
|
$2.07 Million |
|
BioRestorative Therapies Inc
NASDAQ:BRTX
|
$2.07 Million |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
$2.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sonoma Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,137,000 to 4,411,000, a change of -1,726,000 (-28.1%).
- Net loss of 3,457,000 reduced equity.
- Share repurchases of 1,000 reduced equity.
- New share issuances of 3,079,000 increased equity.
- Other comprehensive income decreased equity by 1,653,000.
- Other factors increased equity by 306,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.46 Million | -78.37% |
| Share Repurchases | $1.00K | -0.02% |
| Share Issuances | $3.08 Million | +69.8% |
| Other Comprehensive Income | $-1.65 Million | -37.47% |
| Other Changes | $306.00K | +6.94% |
| Total Change | $- | -28.12% |
Book Value vs Market Value Analysis
This analysis compares Sonoma Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.34x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.34x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-03-31 | $390.14 | $1.20 | x |
| 2003-03-31 | $-32.51 | $1.20 | x |
| 2005-03-31 | $866.93 | $1.20 | x |
| 2006-03-31 | $2784.82 | $1.20 | x |
| 2007-03-31 | $8615.69 | $1.20 | x |
| 2008-03-31 | $3815.52 | $1.20 | x |
| 2009-03-31 | $184.32 | $1.20 | x |
| 2010-03-31 | $436.30 | $1.20 | x |
| 2011-03-31 | $100.30 | $1.20 | x |
| 2012-03-31 | $-46.64 | $1.20 | x |
| 2013-03-31 | $368.99 | $1.20 | x |
| 2014-03-31 | $379.13 | $1.20 | x |
| 2015-03-31 | $191.11 | $1.20 | x |
| 2016-03-31 | $117.56 | $1.20 | x |
| 2017-03-31 | $456.64 | $1.20 | x |
| 2018-03-31 | $304.50 | $1.20 | x |
| 2019-03-31 | $113.52 | $1.20 | x |
| 2020-03-31 | $38.08 | $1.20 | x |
| 2021-03-31 | $26.87 | $1.20 | x |
| 2022-03-31 | $32.78 | $1.20 | x |
| 2023-03-31 | $23.50 | $1.20 | x |
| 2024-03-31 | $6.75 | $1.20 | x |
| 2025-03-31 | $3.55 | $1.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sonoma Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -78.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.20%
- • Asset Turnover: 1.04x
- • Equity Multiplier: 3.10x
- Recent ROE (-78.37%) is above the historical average (-154.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -17.77% | -8.35% | 1.19x | 1.79x | $-261.00K |
| 2003 | 0.00% | -64.57% | 2.57x | 0.00x | $-1.59 Million |
| 2005 | -750.68% | -1219.03% | 0.20x | 3.15x | $-16.75 Million |
| 2006 | -314.79% | -893.92% | 0.20x | 1.73x | $-23.83 Million |
| 2007 | -132.76% | -435.46% | 0.17x | 1.81x | $-21.27 Million |
| 2008 | -131.83% | -530.35% | 0.16x | 1.53x | $-21.88 Million |
| 2009 | -778.14% | -327.69% | 0.99x | 2.40x | $-17.88 Million |
| 2010 | -116.85% | -111.79% | 0.72x | 1.45x | $-8.94 Million |
| 2011 | -467.25% | -81.48% | 1.13x | 5.09x | $-8.12 Million |
| 2012 | 0.00% | -57.51% | 1.63x | 0.00x | $-7.24 Million |
| 2013 | -133.08% | -35.15% | 1.23x | 3.08x | $-5.84 Million |
| 2014 | 30.96% | 27.33% | 0.66x | 1.72x | $2.53 Million |
| 2015 | -68.05% | -59.21% | 0.92x | 1.25x | $-9.41 Million |
| 2016 | -100.22% | -108.46% | 0.68x | 1.36x | $-11.18 Million |
| 2017 | 43.27% | 72.31% | 0.50x | 1.19x | $7.13 Million |
| 2018 | -93.49% | -86.01% | 0.87x | 1.25x | $-15.86 Million |
| 2019 | -112.48% | -62.19% | 1.31x | 1.38x | $-12.85 Million |
| 2020 | -58.82% | -18.45% | 1.23x | 2.59x | $-3.87 Million |
| 2021 | -73.65% | -21.20% | 1.24x | 2.79x | $-4.49 Million |
| 2022 | -58.48% | -40.28% | 0.67x | 2.17x | $-5.96 Million |
| 2023 | -64.57% | -38.81% | 0.82x | 2.03x | $-5.95 Million |
| 2024 | -78.78% | -37.97% | 0.86x | 2.40x | $-5.45 Million |
| 2025 | -78.37% | -24.20% | 1.04x | 3.10x | $-3.90 Million |
Industry Comparison
This section compares Sonoma Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $236,113,024
- Average return on equity (ROE) among peers: -47.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sonoma Pharmaceuticals Inc (SNOA) | $3.43 Million | -17.77% | 2.97x | $2.08 Million |
| Aurora Cannabis Inc (ACB) | $602.92 Million | -11.50% | 0.39x | $197.35 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $340.21 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.77 Billion |
| Amphastar P (AMPH) | $639.42 Million | 21.51% | 1.37x | $959.02 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $287.08 Million | 1.44% | 0.21x | $199.00 Million |
| ANI Pharmaceuticals Inc (ANIP) | $40.96 Million | 0.73% | 0.09x | $1.80 Billion |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more